EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

The predictive value of PD‐L1 expression in patients with advanced hepatocellular carcinoma treated with PD ‐1/ PD‐L1 inhibitors: A systematic review and meta‐analysis

Yao Yang, Dongbo Chen, Bigeng Zhao, Liying Ren, Rui Huang, Bo Feng, Hongsong Chen iD

Cancer Medicine · 2023-04 · 12 (8) · 9282-9292

DOI: 10.1002/cam4.5676 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Medicine, online erschienen am 25.03.2023. Verfasst von Yao Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseas…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Programmed death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) inhibitors have transformed the treatment landscape of advanced hepatocellular carcinoma (HCC), but consistent responses are not observed in all patients, and prognostic biomarkers to guide treatment decisions are lacking. We aimed to evaluate the predictive value of PD‐L1 expression in advanced HCC patients treated with PD‐1/PD‐L1 inhibitors.

Methods

A comprehensive search of PubMed, Embase, Web of Science, and the Cochrane Library was conducted. Studies comparing the objective response rate (ORR) and/or disease control rate (DCR) based on the tumor PD‐L1 status of HCC were included.

Results

Eleven studies with 1,330 HCC patients treated with PD‐1/PD‐L1 inhibitors were included. Pooled odds ratio (OR) analysis demonstrated a significantly improved ORR in PD‐L1‐positive patients compared with PD‐L1‐negative patients (OR, 1.86, 95% CI, 1.35–2.55). Similar results were observed in the anti‐PD‐1 treatment ( p < 0.001) and anti‐PD‐1/PD‐L1 monotherapy ( p < 0.001) subgroups. The pooled ORRs in the PD‐L1‐positive and PD‐L1‐negative groups were 26% (95% CI, 20%–32%) and 18% (95% CI, 13%–22%), respectively. For DCR, the pooled OR analysis showed no significant difference between PD‐L1‐positive patients and PD‐L1‐negative patients (66% [95% CI, 55%–76%] vs. 69% [95% CI, 62%–76%]; OR, 0.92, 95% CI, 0.59–1.44). The results were consistent across the drug target and combination treatment subgroups.

Conclusion

Positive PD‐L1 expression is associated with a better ORR in advanced HCC patients treated with anti‐PD‐1/PD‐L1‐based therapies. This feature can help to identify HCC patients who will benefit most from PD‐1/PD‐L1 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansImmune Checkpoint InhibitorsB7-H1 Antigen

Stichwörter der Autor:innen

biomarkerhepatocellular carcinomaimmune checkpoint inhibitorsmeta-analysisprogrammed death-ligand 1treatment response

Substanzen

Immune Checkpoint InhibitorsCD274 protein, humanB7-H1 Antigen

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing, China.
  • Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China.

ORCID-Profile: Hongsong Chen

Förderung

  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Yang, Y., Chen, D., Zhao, B., Ren, L., Huang, R., Feng, B., & Chen, H. (2023). The predictive value of PD‐L1 expression in patients with advanced hepatocellular carcinoma treated with PD ‐1/ PD‐L1 inhibitors: A systematic review and meta‐analysis. Cancer Medicine, 12(8), 9282-9292. https://doi.org/10.1002/cam4.5676

Vancouver

Yang Y, Chen D, Zhao B, Ren L, Huang R, Feng B, et al. The predictive value of PD‐L1 expression in patients with advanced hepatocellular carcinoma treated with PD ‐1/ PD‐L1 inhibitors: A systematic review and meta‐analysis. Cancer Medicine. 2023;12(8):9282-9292. doi:10.1002/cam4.5676

BibTeX
@article{Yang2023,
  author = {Yang, Yao and Chen, Dongbo and Zhao, Bigeng and Ren, Liying and Huang, Rui and Feng, Bo and Chen, Hongsong},
  title = {The predictive value of PD‐L1 expression in patients with advanced hepatocellular carcinoma treated with PD ‐1/ PD‐L1 inhibitors: A systematic review and meta‐analysis},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {8},
  pages = {9282--9292},
  doi = {10.1002/cam4.5676}
}
Kostenlos starten →